Latest CYCN reports update at 2024-05-07: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Cyclerion Therapeutics CYCN

$ 3.0 4.6%

Cyclerion Therapeutics Balance Sheet 2011-2024 | CYCN

Annual Balance Sheet Cyclerion Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-51.1 M	-21 M	-	-	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	3.29 M	3.42 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	70.5 M	-	-	-	-	-	-	-	-
Total Current Liabilities	2.09 M	7.63 M	11.1 M	17 M	18.2 M	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	55.9 M	88.7 M	17.8 M	14 M	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-264 M	-259 M	-215 M	-	-85.6 M	-	-	-	-	-	-	-	-
Total Assets	13.4 M	18.1 M	59.3 M	115 M	186 M	7.4 M	5.47 M	-	-	-	-	-	-
Cash and Cash Equivalents	7.57 M	13.4 M	54 M	54.4 M	94.9 M	-	-	-	-	-	-	-	-
Book Value	13.4 M	18.1 M	59.3 M	59.5 M	97.7 M	-10.4 M	-8.57 M	-	-	-	-	-	-
Total Shareholders Equity	11.3 M	10.5 M	48.2 M	59.5 M	97.7 M	-10.4 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Cyclerion Therapeutics

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	38.1 M	38.9 M	38.9 M	38.9 M	38.9 M	70.5 M	70.5 M	70.5 M	70.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-266 M	-264 M	-263 M	-270 M	-	-259 M	-252 M	-241 M	-228 M	-215 M	-204 M	-193 M	-177 M	-163 M	-163 M	-163 M	-163 M	-85.6 M	-85.6 M	-85.6 M	-85.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	11.4 M	13.4 M	15.2 M	10.1 M	-	18.1 M	25.1 M	35.2 M	46.5 M	59.3 M	67.7 M	75.7 M	100 M	115 M	115 M	115 M	115 M	186 M	186 M	186 M	186 M	7.4 M	7.4 M	7.4 M	7.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	5.7 M	7.57 M	9.11 M	5.64 M	7.17 M	13.4 M	20.4 M	30.3 M	41.1 M	54 M	62.5 M	70.4 M	41.4 M	58.2 M	54.4 M	54.4 M	54.4 M	94.9 M	94.9 M	94.9 M	94.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	11.4 M	13.4 M	15.2 M	10.1 M	-	18.1 M	25.1 M	35.2 M	46.5 M	59.3 M	67.7 M	75.7 M	100 M	115 M	115 M	115 M	115 M	186 M	186 M	186 M	186 M	7.4 M	7.4 M	7.4 M	7.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	9.92 M	11.3 M	12.9 M	5.15 M	3.92 M	10.5 M	16.5 M	25.4 M	37 M	48.2 M	56.4 M	65.2 M	48.4 M	59.5 M	59.5 M	59.5 M	59.5 M	97.7 M	97.7 M	97.7 M	97.7 M	-10.4 M	-10.4 M	-10.4 M	-10.4 M	-8.57 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency